Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer

BACKGROUND: Bevacizumab, a monoclonal antibody against soluble VEGFA, is an approved and commonly administered anti-angiogenic drug in patients with metastasized colorectal cancer (mCRC). The survival benefit of anti-VEGF therapy in mCRC patients is limited to a few months, and acquired resistance m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qing, Perakis, Samantha O., Ulz, Peter, Mohan, Sumitra, Riedl, Jakob M., Talakic, Emina, Lax, Sigurd, Tötsch, Martin, Hoefler, Gerald, Bauernhofer, Thomas, Pichler, Martin, Gerger, Armin, Geigl, Jochen B., Heitzer, Ellen, Speicher, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036260/
https://www.ncbi.nlm.nih.gov/pubmed/32087735
http://dx.doi.org/10.1186/s13073-020-0719-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036260/
https://www.ncbi.nlm.nih.gov/pubmed/32087735
http://dx.doi.org/10.1186/s13073-020-0719-6

Ejemplares similares